News Hub | News Direct

News Release

BNB's Binance Launches Memecoin Staking Opportunity, Cardano Consolidates After Rally, InQubeta Aims for $1 in 2023

Web3 AI Media

The crypto landscape is buzzing with activity. Recently, Binance, the largest centralized exchange in the crypto space, announced a new staking opportunity for the community. The Binance Launchpool debuted Memecoin (MEME) staking opportunities for the holders of BNB, TUSD, and FDUSD. This provides an opportunity to earn, which has been met with excitement, unsurprisingly. In other news, Cardano (ADA) is in a consolidation phase after a period of rallying. Meanwhile, InQubeta (QUBE), one of the new ICOs (initial coin offerings), is aiming for $1 before the end of the year. In this article, we will cover the launch of Memecoin staking by Binance. In addition, we will explore the decline in the momentum of Cardano. Finally, we will delve into InQubeta’s potential, including why it is one of the altcoins to watch out for in the coming months. InQubeta (QUBE): The Road to $1 In contrast to Cardano and BNB, InQubeta (QUBE) is a new player in the crypto space. It is an innovative project on the initial coin offering list, popular for blending AI and blockchain technology, and has been stirring up interest. What is the significance of InQubeta’s convergence of AI and blockchain? It aims to transform the fundraising landscape of the AI sector by leveraging blockchain technology. To achieve its goal, it will become the first crowdfunding platform for AI startups through crypto, using its utility token, QUBE. This project is in the fourth stage of its presale phase and has managed to raise a whopping $4.3 million. Its current price is $0.0161, and analysts predict it will reach the $1 mark before mid 2024. This makes it arguably the best new crypto to invest in. If you wish to become an early adopter of this intriguing project, simply follow the link below. Visit InQubeta Presale Binance Launches Memecoin Staking The development that has taken a part of the crypto community by storm is the introduction of Memecoin (MEME) as a new staking opportunity. This token is currently featured on the Binance Launchpool staking platform. But what is Memecoin? It is the native utility token of Memeland, a Web3 venture studio. Binance plans to distribute 2% of the total supply of Memecoin, over 1.3 billion, to users on the Launchpool. Holders of BNB and the stablecoins TUSD and FDUSD can earn Memecoin by staking their holdings. Notably, this exercise will be held between October 28 and November 26. So, if you haven’t started staking, now is the best time to do so. Cardano (ADA) is in a Consolidation Phase What is Cardano (ADA)? At this point, it requires little to no introduction. After all, it is one of the top altcoins in the market and a top ten cryptocurrency. Simply put, it is a proof-of-stake (PoS) blockchain platform that allows the development of decentralized applications (dApps) and smart contracts. Therefore, Cardano is integral to the blockchain landscape. Although Cardano has real-world applications and a solid foundation, it is currently in a consolidation phase. Nevertheless, it is worth noting that before this, ADA was on the upside. So, what will be its next move? Well, it is uncertain for now. Nevertheless, Cardano is expected to rally in the future, making it a good crypto to buy. Conclusion The unveiling of Memecoin as a new staking opportunity has been met with enthusiasm within the crypto community. In addition to this, Cardano is consolidating, while InQubeta has its sights set on the $1 mark. InQubeta’s fundamentals and investor interest in it will both play an important role in its rise. Visit InQubeta Presale Join The InQubeta Communities Contact Details Solomon marketing@inqubeta.ai

November 06, 2023 09:15 AM Eastern Standard Time

How IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Past

Benzinga

By Ted Stavetski, Benzinga IN8bio Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company tackling one of society’s most pressing issues: cancer. Specifically, the company is focused on using the immune system to eliminate residual tumors, and currently has two clinical programs focused on leukemia and on glioblastoma, the deadliest type of brain cancer. IN8bio is pioneering a new approach using the immune system to tackle the deficiencies that plague most current cancer treatments. Alpha-beta T cell-based chimeric antigen receptor, or CAR-T therapies have shown remarkable results against some leukemias and myelomas. However, many of these CAR-T treatments have faced challenges against more difficult-to-treat leukemias, such as acute myeloid leukemia (AML) and solid tumor cancers. These cancers can be highly heterogenous, making them difficult to kill since they are often intertwined in healthy tissues, leading to unintentional toxicities and adverse events. In some cases, patients have even died. Fortunately, IN8bio may have found the solution to this problem. What Is “Cancer Zero?” IN8bio set out on a mission that it calls “Cancer Zero”, which co-founder and CEO William Ho describes as “the goal of pursuing the safe eradication of all tumor cells in patients fighting cancer.” In other words, the company aims to eliminate all cancer cells without destroying healthy cells. To achieve this, the company has developed advanced technologies using a specific subset of immune cells, or lymphocytes called gamma-delta T cells, in its DeltEx platform. Gamma-delta T cells are white blood cells whose job in the body is to be a first-responder and to determine safe and not-safe. They kill invading or dangerous cells and can call in reinforcements by recruiting and activating other immune cells. It was IN8bio’s co-founder, Dr. Lawrence Lamb, a clinical immunologist on a cancer ward treating patients with aggressive leukemias in the 1990s, who made the first observation that gamma-delta T cells are linked to greater survival in cancer patients. He spent the next 25 years figuring out how to expand, genetically engineer and manufacture gamma-delta T cells at scale and into a cancer therapy. In 2016, IN8bio was launched to take these gamma-delta T cell technologies into the clinic and today, Dr. Lamb is IN8bio’s Chief Scientific Officer. He leads a team of scientists and researchers dedicated to achieving the company’s mission of Cancer Zero. IN8bio’s DeltEx platform uses gamma-delta T cells that it believes are potentially safer and more effective at killing cancer cells than other therapies currently in development. The company has the capability to utilize autologous (from the patient), allogeneic (from a donor or “off-the-shelf”) and induced pluripotent stem cell (iPSC)-derived gamma-delta T cells. These cells can be expanded, activated and genetically engineered outside of the body to increase their numbers and to enhance their hunting and killing abilities. In one platform unique to IN8bio, its drug resistant immunotherapy (DRI) technology enhances gamma-delta T cells by genetically engineering them to be chemotherapy resistant. Chemotherapies have been a mainstay of front-line cancer therapy since World War II. While effective at shrinking a tumor and prolonging survival, they also kill white blood cells. As a result, microscopic residual tumors that are resistant to therapy often remain and result in relapse because of the weakened immune system. IN8bio’s DRI approach allows the simultaneous combination of chemotherapy with an immune therapy that may create synergies that allow the DRI gamma-delta T cells to recognize and eliminate the residual tumor cells while leaving healthy tissues alone. By targeting compartments of residual tumor cells, IN8bio’s DRI approach may achieve deeper tumor responses that can prolong survival. The company has already protected the DRI technology behind this process with issued patents around the world. IN8bio: Drugs In Clinical Development IN8bio has three therapies that are in varying stages of clinical development: INB-400: A phase 2 multi-center clinical trial for the treatment of newly diagnosed glioblastoma, or GBM ( NCT05664243 ). This trial has recently initiated enrollment at leading brain tumor centers across the United States following clearance of a company-sponsored investigational new drug application, or IND, by the U.S. Food and Drug Administration, or FDA. This program received Orphan Drug Designation (ODD) from the FDA in the spring of 2023 for targeting a significant unmet medical need, which offers potential incentives such as 7-year market exclusivity. INB-200: A phase 1 clinical trial at the University of Alabama at Birmingham using autologous, genetically modified DRI gamma-delta T cells for the treatment for newly diagnosed glioblastoma (UAB - NCT04165941 ). This program was one of only four central nervous system (CNS) cancer programs to have received an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest world-wide yearly gathering of cancer clinicians and researchers. At that time, the company released initial phase 1 data showing that 100% of treated patients have exceeded expected median progression-free survival. An additional clinical update is expected in November 2023 at the Society for Neuro-Oncology Annual Meeting (SNO), and long-term follow-up data is expected to be presented at medical meetings in the first half of 2024. INB-100: A phase 1 trial for the treatment of patients with high-risk leukemias undergoing haploidentical stem cell transplantation, or HSCT ( NCT03533816 ). The company presented a clinical update at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting in April 2023 that demonstrated 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free and in durable complete remission (CR) as of April 21, 2023. Patients included high-risk AML patients and a patient with acute lymphoblastic leukemia (ALL) who had failed four prior lines of therapy, including CAR-T. All evaluable patients remained alive as of the last assessment and one patient had survived for three years. IN8bio has completed primary enrollment of the phase 1 clinical trial, with updated results expected at the American Society of Hematology (ASH) Annual meeting in December 2023. Topline long term follow ups are expected in 2024. To further its research, IN8bio recently opened a new 10,000-square-foot research & development (R&D) facility in Birmingham, Alabama. This state-of-the-art facility not only bolsters the company’s ability to advance its groundbreaking pipeline of gamma-delta T cell therapies, but also further taps into the advanced cancer research at the UAB, and other prominent institutes. Additionally, the company holds a total of 19 granted U.S. and international patents with many more still pending approval. This will help IN8bio protect its innovative new therapies from competitors as they proceed through clinical trials towards future commercialization. Cancer Immunotherapy Market IN8bio is tackling a large market. Grand View Research estimates that the global cancer immunotherapy market was worth approximately $115 billion in 2022 and is expected to grow at a compound annual growth rate of 8.7% from 2023 to 2030. Diving deeper, the American Cancer Society estimates that there will be 59,610 new cases of leukemia (and 23,710 deaths) in 2023, and the National Brain Tumor Society estimates that there were 13,400 new cases of glioblastoma in 2022. Despite being a lesser-known disease, awareness of glioblastoma is growing quickly. This is mainly due to the unfortunate, high-profile deaths of the President’s son, Beau Biden, and former U.S. Senator John McCain. One Step Closer Towards Cancer Zero IN8bio’s portfolio of cell therapies has the potential to offer a better treatment option for patients suffering from difficult to treat solid and liquid tumors such as AML and glioblastoma. The company’s primary advantage is its patent-protected platform gamma-delta T cell technologies, which it believes may allow it to better target cancer cells, getting deeper responses without hurting the patient’s healthy cells. The biotechnology company has had its foot on the gas pedal in recent years, boasting the following achievements: Two programs in phase 1, and enrollment has been initiated in its corporate-sponsored phase 2 trial at multiple sites across the U.S. A portfolio of preclinical programs in development including: iPSC derived gamma-delta T cells platform. iPSCs represent a significant step toward next generation approaches of cellular manufacturing for true allogeneic and potentially ‘off-the-shelf’ cellular therapies. INB-300, which focuses on addressing various solid and liquid tumors using a dedicated gamma-delta non-signaling CAR-T, or nsCAR, construct. These nsCAR constructs are designed specifically for the biology of gamma-delta T cells and allow IN8bio to potentially target tumor tissues while leaving healthy tissue alone. This could potentially create safer and more potent therapies. 19 granted patents for its technology. A brand new state-of-the-art R&D facility. $17 million in cash on hand, as of June 30, 2023, to help fund its operations and drug development. While the company is currently unprofitable – posting a net loss of $7.7 million for the three months ended June 30, 2023 – this is largely expected for biotechnology companies in the clinical development stage as they work to develop new drugs. However, IN8bio’s approach to business appears to be quite different in the biotechnology industry. The company reports it has been able to advance its clinical and preclinical programs by being extremely efficient with the capital raised, searching for innovative ways to advance their preclinical and clinical programs. Whereas IN8bio has successfully advanced multiple programs into phase 1 and 2 clinical trials while only having spent $76.5 million through 2Q23, a number of competing cell therapy companies have spent far more while showing similar, or less progress. Co-founder and CEO, William Ho has over 22 years of combined experience managing biotechnology companies, healthcare finance and investing, while co-founder and CSO, Lawrence Lamb has been in cellular therapy for three decades. They and the rest of the management team have the experience and know-how to effectively execute, manufacture, develop and advance the company’s growing portfolio of cancer therapies. With any luck, IN8bio will be able to achieve their mission of Cancer Zero, making cancer a thing of the past. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

Where Is Your Doctor Investing? Chances Are It Could Be DLP Capital – A Deep Dive Into The Returns Offered By The Firm’s Housing-Focused Funds

Benzinga

By Austin DeNoce, Benzinga Physicians, after years of intensive training and practice, are known for their rigorous and methodical approach when making decisions that impact their patients' health. This same attention to detail can often extend to their financial investments, and many are curious about where successful doctors invest their money. Treating patients, like investing, requires intelligence and patience. Among the myriad of investment choices available, DLP Capital emerges as an interesting choice due to its comparable ethos reflected in its broader vision of positively impacting society, and doctors seem to have taken notice – the company reports doctors have invested over $260 million in DLP Capital’s housing-focused funds. A Glimpse Into DLP Capital's Portfolio Since it was founded in 2006, DLP Capital has solidified its position in the investment landscape, earning a spot on the Inc. 5000 Fastest-Growing Companies list and retaining it for 11 consecutive years. The firm manages assets valued at over $5 billion, drawing support from a diverse pool of more than 2,600 investors. Owning and overseeing over 18,000 housing units, several of their funds have met or even surpassed their targeted returns. Through their varied endeavors, DLP Capital claims to have positively impacted more than 838,000 lives. Historical Returns: A Snapshot DLP Lending Fund: With a target annual return of 9-10%, this fund managed a 12.71% annual return as of September 30, 2023. As a private REIT emphasizing rental housing in high ownership-cost areas, it offers investors liquidity, a rigorous borrower vetting process and a 90-day redemption period without long-term constraints. Prioritizing investor returns, all preferred payouts are dispensed before any management fees, and invested capital retains a top-tier position, ensuring payment precedence over common equity participants. DLP Building Communities Fund: With an ambitious target of 11-13%, this fund achieved an annual return of 12.81% by the end of 2022. Designed as an evergreen private real estate fund, it focuses on developing new rental communities for attainable housing while providing a measure of protection against stock market volatility, consistent asset valuation for growth and flexible redemption options. All returns are prioritized to investors before any management fee is levied, ensuring their capital retains a preferred, high-priority position in all deals. DLP Preferred Credit Fund: This fund achieved a return of 10.52% in Q2 for 2023 on its 10-11% annual target, emphasizing insulation against rising interest rates and ensuring liquidity. By rigorously vetting borrowers and prioritizing loans to seasoned real estate sponsors, the fund ensures investors enjoy a preferred payment position and monthly returns before management fees, aligning the interests of DLP with its investors. Focusing on debt and preferred credit investments in the Sun Belt, its intent is to make a dent in America's affordable housing crisis, ensuring that rentals are attainable for working families. DLP Housing Fund: Perhaps the most eye-catching of the lot, DLP reports this fund saw an annual return of 27.04% by September 30, 2023, much higher than its annual target of 10-11%. By investing equity in multifamily rental communities (including manufactured housing and RV), the fund emphasizes both renter affordability and investor returns. The fund operates as an open-ended, private real estate venture focusing on long-term assets to yield enhanced returns. Investors not only benefit from tax advantages like depreciation offsets and 1031 tax-deferred exchanges, but they also enjoy flexible annual redemptions and a preferred position, guaranteeing payment priority over common equity investors. With returns like this, DLP may seem like a natural choice for many, but doctors are being attracted to DLP Capital for multiple reasons. The Attraction Of Passive Income One of the primary draws for busy professionals – such as those in the medical field – is the concept of passive income. They can enjoy the fruits of their investments without the daily demands of active engagement. DLP Capital's offerings, especially with its history of consistent returns, specifically aim to satisfy this demand for passive income – and doctors seem to find them particularly appealing. Impact Investing: Partnering With Doctors To Do Good Professionals like doctors frequently align their investment choices with societal benefits. Given the intrinsic desire among many in the medical profession to contribute positively to society, there's potential interest in DLP Capital, primarily due to its initiatives in affordable housing. Specifically, the DLP Housing Fund focuses on rental housing aimed at those with incomes near the area median. Likewise, the DLP Preferred Credit Fund and the DLP Building Communities Fund incorporate rental affordability into their strategies. Consequently, these funds combine financial objectives with addressing a relevant societal challenge. Exceeding Expectations DLP Capital has maintained a consistent investment record. Since its founding in 2006, there have been no reported capital losses for investors. Such reliable performance, alongside the size of potential returns, are important considerations for those evaluating investment options. Some of DLP Capital's funds have also achieved returns beyond their initial targets, reflecting reasonable success for some of its investment strategies. At the very least, their performance suggests a capacity to meet and occasionally exceed market expectations, though past performance is not a guarantee of future performance. Don Wenner, the CEO of DLP Capital, has played a significant role in the firm's direction. With over 16,000 real estate transactions amounting to more than $4 billion since 2006, his experience is extensive. Leveraging his experience, DLP's overarching mission includes both profit generation and broader goals to positively influence millions of lives. DLP Capital's Prognosis DLP Capital has positioned itself within the investment space by emphasizing passive income, societal impact and consistent returns – and successful professionals like doctors seem to be paying attention, with over a quarter of a billion invested by the medical community. The firm offers a comprehensive approach that integrates passive revenue streams, initiatives in affordable housing and a track record that reflects its strategy and performance over time. All returns aside, DLP Capital's alignment with affordable housing initiatives echoes the ethos of many in the medical profession and could be attractive to others, especially those seeking to yield a positive societal impact through their investments. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

News Release

Tron Continues Its Uptrend, Bitcoin Cash Is Stagnant, BorroeFinance Investors Are Bullish

Blockchain Digest

Per recent market data, Tron (TRX) is in a sustained rally alongside its Total Value Locked (TVL), which has just obtained a record high. On the flip side, Bitcoin Cash (BCH) continues its protracted passiveness as the bulls struggle to overhaul the bears. Meanwhile, investors remain bullish on the new DeFi project BorroeFinance ($ROE) as it gears up for a parabolic surge. Let’s find out which of these top crypto coins investors may likely delve into. >>BUY $ROE TOKENS NOW<< Tron Surges 9% As TVL Hits All-time High On October 28, market data revealed an impressive development within the Tron (TRX) chain. Accordingly, Tron (TRX) has managed to perform excellently in recent times, setting new records. In particular, the blockchain authorized 6.5 billion transactions, indicating the efficacy and robustness of the Tron (TRX) network. At the same time, Tron’s Total Value Locked (TVL) hit a new milestone of $6.75 billion, accompanied by a 2.23% increase. These impressive demonstrations significantly affected Tron’s native token, TRX. Notably, TRX registered a 9.27% increase between October 16 and October 29. During this period, Tron (TRX) rose from $0.0866 to $0.0948. Due to Tron’s current trajectory, analysts posit that TRX is bound to climb to higher levels. More precisely, they expect to see TRX gain 4.3% to $0.1 in the coming term. Miners Are Dilemmatic Over Bitcoin Cash On-chain activities data showed that Bitcoin Cash (BCH) miners have been on a selling spree over the past month. This selloff resulted in a massive drop in the price of Bitcoin Cash (BCH). On October 24, BCH withdrew from the $265 price range following a period of sharp correction. This pullback represented a 3.85% drop in the price of Bitcoin Cash (BCH). However, as the selloff slowed down, Bitcoin Cash (BCH) witnessed an impulsive bounce. On the weekly timeframe, BCH gained 13.16% on its market value between October 16 and October 22. However, the selling pressure eventually weighed heavily on Bitcoin Cash as BCH only rose 1.11% between October 23 and October 29. This slowdown in activity led experts to assert that Bitcoin Cash (BCH) might maintain this pace in the forthcoming sessions. As a result, they predict that BCH may linger around $242, a 0.1% increase from the current price until significant news or development touching Bitcoin Cash surfaces. BorroeFinance Investors Are Bullish On $ROE BorroeFinance ($ROE) is regarded as one of the best cryptocurrency investment options for both savvy and novice investors. This sentiment is predicated on the capabilities of the platform and the growth map of $ROE. BorroeFinance caters to the needs of buyers and sellers in the Web3 space, making it a pivotal project for people involved in Web3. >>BUY $ROE TOKENS NOW<< BorroeFinance is a marketplace that uses artificial intelligence tools to carry out its services to users. It offers content creators within the Web3 world a platform to trade their future earnings for instant greenbacks. The platform connects buyers and sellers while ensuring that the needs of both parties are duly served. The reason BorroeFinance is considered one of the top DeFi projects in existence is because of its impact on the finance world. BorroeFinance ($ROE) helps businesses and individuals raise funds through an easy and less hectic procedure. The platform is targeted to launch on the Polygon blockchain alongside its native token, $ROE. BorroeFinance is currently in Stage 2 of its public presale, with $ROE trading at $0.015. Investors have the opportunity to benefit from a 167% surge when $ROE hits $0.040 at the end of the presale. Not only that, the token’s value is bound to increase after its official launch on exchanges, creating borderless avenues for investors to earn. Learn more about BorroeFinance ($ROE) here: Visit BorroeFinance Presale | Join The Telegram Group | Follow BorroeFinance on Twitter Contact Details Borroe Finance media@borroefinance.ai

November 03, 2023 10:07 AM Eastern Daylight Time

News Release

Arbitrum Dominates Layer 2 Protocols, BorroeFinance Empowers Web3 Growth Using AI

Blockchain Digest

Arbitrum (ARB) recently recorded another ecosystem win that further cemented its top position among L2 blockchains. While Arbitrum (ARB) built a program that will help developers build better Dapps, BorroeFinance ($ROE) is promoting web3 growth by bridging short-term liquidity gaps in the industry. Let’s see what experts are saying about these two tokens and their predictions for the future. >>BUY $ROE TOKENS NOW<< ARB Surges Amid Positive Ecosystem Development On October 26, Arbitrum (ARB) announced that its long-anticipated Arbitrum Orbit is ‘mainnet-ready.’ The Arbitrum Orbit project will allow blockchain developers to build decentralized apps and new DeFi projects with cutting-edge technology. In addition, developers can create their customized L3 blockchain on any Arbitrum L2 blockchain. The Arbitrum Orbit project has put Arbitrum (ARB) ahead of other L2 blockchains like Optimism and Polygon. Steven Goldfeder, CEO of Offchain Labs, also shared his opinions on the functionalities of Arbitrum Orbit. The CEO said this level of customization and flexibility is a game changer. Arbitrum Orbit will open doors to a new sub-group of L3 blockchain engineers, resulting in an ecosystem expansion. As a result of this positive ecosystem development, ARB gained 9.51% in the last week of October. On October 23, ARB traded at $0.8732. A week later, ARB surged and traded at $0.9591. According to analysts, ARB is at the beginning of its bull rally, and the token could hit $1.5500 in Q1 2024. BorroeFinance: AI Meets Blockchain in New Decentralized Fundraising Platform BorroeFinance ($ROE) is the world’s first web3 blockchain invoice discounting NFT marketplace. This AI-powered fundraising platform allows web3 businesses to generate instant cash by selling future digital earnings. Web3 participants on BorroeFinance ($ROE) can mint their future subscriptions, invoices, and royalties into popular NFTs and sell them to supportive communities at discounted prices. >>BUY $ROE TOKENS NOW<< Supportive communities are active followers on your web3 brand willing to support your business by providing loans to meet immediate short-term liquidity needs. BorroeFinance protects buyer investments by incorporating AI risk assessment, efficient payment solutions, and blockchain technology into its protocol. According to experts, this loan request protocol will guarantee a safe, secure, and straightforward fundraising process. Thankfully, this high-utility project is still in its early stages, and savvy investors are buying the $ROE for $0.015. When $ROE finally hits the mainstream market, the token will surge 167% and trade for $0.040 on major crypto exchanges. If expert predictions play out, $ROE will record fast market adoption and may trade for $0.100 by June 2024. Learn more about BorroeFinance ($ROE) here: Visit BorroeFinance Presale | Join The Telegram Group | Follow BorroeFinance on Twitter Contact Details Borroe Finance media@borroefinance.ai

November 03, 2023 10:05 AM Eastern Daylight Time

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System

Benzinga

By Jeremy Golden, Benzinga An estimated 609,820 people will die of cancer in the United States this year, according to the National Cancer Institute. Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic about the future of treating this deadly disease. With its proprietary Amphiphile or “AMP” platform, Elicio Therapeutics Inc. (NASDAQ: ELTX) has developed multiple cancer vaccine candidates that concentrate an array of different immunogens in the lymph nodes. ELI-002 is Elicio’s lead clinical program for Kirsten rat sarcoma (KRAS) driven cancers caused by a mutation of the KRAS gene. An “off the shelf” approach designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors, ELI-002 is currently being studied in AMPLIFY-201 – a phase 1 dose escalation study – and AMPLIFY-7P, a phase 1/2 study. In September, Elicio released new information about the vaccine candidates in its pipeline at the ninth AACR Special Conference on Pancreatic Cancer in Boston. The positive preliminary relapse-free survival (RFS) data from the ongoing AMPLIFY-201 study demonstrated an 86% reduction in risk of progression or death in patients with large T-cell responses induced by ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS. Despite the AMPLIYF-201 study not including a control arm, the median RFS of over 16 months is significantly longer than what has been seen in other studies of similar patient groups. “Patients with mutant KRAS cancers, particularly pancreatic and colorectal cancers, have a poor prognosis with limited treatment options when tumor DNA or protein biomarkers are detected after standard surgery and chemotherapy,” said Eileen M. O’Reilly, M.D., Winthrop Rockefeller Endowed Chair of Medical Oncology and Co-Director of Medical Initiatives at David M. Rubenstein Center for Pancreatic Cancer Research. “We are encouraged by the early data showing ELI-002 induced T cells can positively impact clinical endpoints including the risk of relapse and death in this study.” Targeting Immunogens To Lymph Nodes Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, which are located throughout the body on the lymphatic vessels at various intervals along the lymphatic routes. During the process of circulating throughout the lymphatic system, lymph fluid accumulates antigens and other biomolecules captured from the tissues. This fluid then drains into the lymph nodes, where it encounters T cells and B cells congregating together with antigen-presenting cells (APCs). Targeting the immunogens in the lymph nodes has been proven to result in tumor or pathogen-targeted immunity, including potent T cell and humoral responses, in preclinical trials. Alongside AMPLIFY-201, ELI-002 7P is currently being studied in AMPLIFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. Designed to provide immune response coverage against seven of the most common KRAS mutations, the ELI-002 7P formulation increases the potential patient population for ELI-002 while possibly reducing the chance of bypassing resistance mechanisms. Moving forward in early 2024, Elicio Therapeutics plans to initiate a randomized phase 2 trial studying ELI-002 7P as a monotherapy in adjuvant PDAC patients. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 03, 2023 09:00 AM Eastern Daylight Time

QYOU Media Appoints Former TikTok Country Manager Raj Mishra as India Group CEO Overseeing All Operations

QYOU Media

Contact Details Doug Barker +1 437-992-4814 shareholder@qyoutv.com Company Website https://www.valuethemarkets.com

November 02, 2023 12:00 PM Eastern Daylight Time

Video

News Release

Which Stocks Are Primed For India's HUGE Social Media Market?

QYOU Media Inc

ValueTheMarkets News Commentary - India is on course to soon become the planet's biggest social media market, with the country gaining some serious ground on China. According to Statista, India's 1.18 billion unique users will be just 33 million behind the top spot. This article examines who is seeking to capitalize on this huge market with reference to Meta Platforms Inc (NASDAQ: META), Snap Inc (NYSE: SNAP), Alphabet (NASDAQ: GOOGL) and QYOU Media (TSXV: QYOU) (OTC: QYOUF). Meta Platforms enjoys a dominant position in terms of platforms and uses India to test out new monetization strategies. Alphabet has an already hugely successful product in the country, and one of its features looks set to go from strength to strength. Finally, Snap is seeking to leverage its massive audience in the country. QYOU Media (TSXV: QYOU) (OTC: QYOUF) produces and distributes content created by social media stars. It has a multitude of TV channels and platforms and is attracting a rapidly growing audience. Now, the business has brought in bonafide social media royalty to push it to the next stage. It has appointed Indian digital leader and strategist, Raj Mishra, to the role of Group CEO of its India operations. Mishra has held leading roles in some of the most successful app businesses in India. This includes an instrumental role at Musical.ly (now TikTok), leading it to over 150 million monthly active users. He served as Country Head and led Musical.ly to become the most downloaded app on Android and iOS app stores. He oversaw the rebranding transition from musical.ly to TikTok after its 2017 acquisition wherein it racked up 611 million downloads in under three years. Meta Platforms Inc (NASDAQ: META) is dominant in the Indian social media market. The company's flagship Facebook app has a 55% market share in the country, according to data from July 2023 provided by Statista. Additionally, the same source has its Instagram app as the second biggest platform in the country, with a market share of 36%. Such is the might of the platforms that they have both been confident enough to launch new paid subscription services for Indian users who want an ad-free experience. This is symptomatic of how the company has been operating Facebook, Instagram and WhatsApp in the country, with the Financial Times noting that India is often used as something of a testing ground. As well as introducing subscription fees, innovations include click-to-message ad formats. These connect customers and businesses within various chat applications, with the company taking home commission from all business done via the route. Alphabet (NASDAQ: GOOGL) has a huge interest in Indian social network users too. That's because India is the largest audience for the company's YouTube video sharing and social media platform. Data from Statista shows that 462 million Indians tuned in to YouTube in October 2023, with the United States in a distant second place with 236 million. What this tells us is that India is hugely important for YouTube and, by extension, its parent company. The business has a major edge in the country too. With Chinese mega-app TikTok having been banned in India three years ago, the short-form video content space is missing a major competitor. YouTube's "Shorts" feature is going a long way to filling this void, helping the company to maintain its huge numbers of viewers in the country. Snap Inc (NYSE: SNAP) is another business we must discuss when touching on short-form video. Snap has also become hugely popular in India, with figures from Statista showing that its user base is 59% higher than that of the United States. If nothing else, this is a testament to how crazy about social media the Indian population is! But there is still room to grow, according to forecasts. Projections from Statista indicate that, following a ninth consecutive annual increase in user base, the platform will reach 158.63 million users and therefore a new peak in 2027. But how is the company seeking to capitalize on this user base? Like QYOU Media, the company has recently appointed an industry star to run its Indian operations in the form of former Google executive Pulkit Trivedi. With sagging revenues, the app is reportedly targeting India for new growth amid efforts to localize services and shore up ad revenues. India is a massive prospect for social media-savvy companies. But there are multiple routes to taking advantage of this exciting opportunity. QYOU Media has achieved consistent quarterly YoY revenue growth and has brought in a social media whiz to push things to the next level. Meta Platforms is rolling out subscription fees and new ad technology, while Alphabet is taking advantage of short-form video. Finally, Snap is trying to solve the puzzle of its lagging revenues through localization. IMPORTANT NOTICE AND DISCLAIMER PAID ADVERTISEMENT This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the "Publisher") is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by QYOU Media Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and twenty five thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher's ability to provide unbiased information or opinion. CHANGES IN SHARE TRADING AND PRICE Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur. NO OFFER TO SELL OR BUY SECURITIES This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. INFORMATION Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. This communication is based on information generally available to the public and on an interview conducted with the company's CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views. NO FINANCIAL ADVICE The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual's financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company's SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. FORWARD LOOKING STATEMENTS This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company's actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company's operations; the size and growth of the market for the company's products and services; the company's ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company's business. INDEMNIFICATION/RELEASE OF LIABILITY By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions. TERMS OF USE AND DISCLAIMER By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications. INTELLECTUAL PROPERTY All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com. AUTHORS: VALUETHEMARKETS valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above. Contact Details ValueTheMarkets +44 141 530 4080 editor@valuethemarkets.com Company Website https://www.valuethemarkets.com

November 02, 2023 11:00 AM Eastern Daylight Time

Bravo’s The Real Housewives of New York Stars Erin and Abe Lichy Launch Mezcal Brand: Mezcalum

Mezcalum

Husband and wife duo Abe and Erin Lichy, serial entrepreneurs and breakout stars of Bravo’s The Real Housewives of New York, announced today the launch of Mezcalum - an artisanal, organic mezcal embodying time-honored Mexican traditions and the rich heritage of its spirit. Carefully crafted with a proprietary blend, Mezcalum is zero sugar, zero carb, and features 100% organic ingredients with no additives. With its launch, Mezcalum is on a mission to make mezcal sexy and transform the way consumers drink with a sophisticated and purposeful experience. “Mezcalum was an idea born from our love of drinking mezcal with family and friends in Tulum,” said Erin Lichy, Co-Founder of Mezcalum. “Inspired by the exuberant city and its rich culture, we set out to pay our tribute to Tulum with a unique Mezcal blend by marrying the Oaxacan culture and sexy beach vibe of Tulum. As an entrepreneur, mother and real estate agent, developer and designer, balance is key in my life, and Mezcalum offers just that; I can sip on it at night, and still wake up feeling refreshed and ready to conquer my day. Mezcalum is designed to be the spirit for wellness warriors.” Crafted with a proprietary blend of Espadin Agave and Cuishe (44% ABV), a rare and wild variety that only grows in highly specific regions in the central valleys of Oaxaca, Mezcalum is an all-natural spirit with low smoke-flavor levels, complex undertones and a great depth for a palatable taste. Handcrafted in Oaxaca, Mezcalum is created at a family-owned-and-operated distillery, Doov Yaal, with over 100 years of artisanal crafting experience. Committed to ethical and sustainable, farm to bottle practices, Maestro Mezcalero Carlos Mendez Blas selects and harvests agave hearts by hand when they’re at their peak, then roasts, ferments, and distills them using artisanal methods guided by generations of ancestral wisdom. “We created Mezcalum for all those who value wellness and balance, yet enjoy a nice drink at the end of the day”, said Mezcalum’s Co-Founder Abe Lichy. “Mezcal is not only one of the oldest distilled agave spirits and “father of tequila”, but also the purest agave spirit, offering among the lowest sugar and calorie counts of any spirit. Historically, Mezcal has been known as a rugged spirit that attracts a more masculine audience - but with Mezcalum, we are making the rich-history spirit more accessible, catering to anyone and everyone who enjoys a high-quality, artisanal sip. It has been a truly special experience for my wife and I to team up with our childhood friend, Chris, to bring a spirit to market that celebrates togetherness and invokes lifelong memories.” In addition to Erin and Abe bringing on their lifelong friend, Chris Roth as their third co-founder, the dynamic duo has an impressive roster of investors and advisors including the ‘curator of pop culture,’ Deuxmoi and New York Jets Wide Receiver, Randall Cobb. Passionate about philanthropy and giving back to Mexico, Mezcalum has committed to donate a portion of sales to a Mexico-based sustainability charity. More details to come. Mezcalum is now available for $49.99 in limited quantities at mezcalum.com with plans to expand beyond direct-to-consumer in select Tri-State retailers in December 2023 and nationally in 2024. For more information visit mezcalum.com or follow @mezcalum on Instagram. About Mezcalum: Mezcalum is a premium, artisanal mezcal brand founded by The Real Housewives of New York stars and entrepreneurial husband and wife duo Abe and Erin Lichy. Handcrafted in Oaxaca using time-honored Mexican traditions at a family-owned-and-operated distillery, Mezcalum is committed to ethical and sustainable, farm to bottle practices. Recreating the way we drink by offering a sophisticated and mindful experience, Mezcalum is crafted with a proprietary blend, zero sugar, low calories, 100% organic ingredients and zero additives. For more information, follow @mezcalum or visit mezcalum.com. Contact Details Powers PR Courtney Stewart mezcalum@powers-pr.com Company Website https://www.mezcalum.com/

November 02, 2023 10:03 AM Eastern Daylight Time

Image

Entertainment

BNB's Binance Launches Memecoin Staking Opportunity, Cardano Consolidates After Rally, InQubeta Aims for $1 in 2023

How IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Past

Where Is Your Doctor Investing? Chances Are It Could Be DLP Capital – A Deep Dive Into The Returns Offered By The Firm’s Housing-Focused Funds

Tron Continues Its Uptrend, Bitcoin Cash Is Stagnant, BorroeFinance Investors Are Bullish

Arbitrum Dominates Layer 2 Protocols, BorroeFinance Empowers Web3 Growth Using AI

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System

QYOU Media Appoints Former TikTok Country Manager Raj Mishra as India Group CEO Overseeing All Operations

Which Stocks Are Primed For India's HUGE Social Media Market?

Bravo’s The Real Housewives of New York Stars Erin and Abe Lichy Launch Mezcal Brand: Mezcalum